Evidence map›Paper›PMID 29315352›Full record

ArticlePloS one2018

Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.

Berthold Bivigou-Mboumba, Marie Amougou-Atsama, Samira Zoa-Assoumou, Hervé M'boyis Kamdem, Guy Francis Nzengui-Nzengui, Angélique Ndojyi-Mbiguino, Richard Njouom, Sandrine François-Souquière

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Berthold Bivigou-MboumbaUnité Mixte de Recherches VIH et Maladies Infectieuses Associées (UMR VIH-MIA), Centre International de Recherches Médicales (CIRMF), Libreville, Gabon.ORCID 0000-0003-0662-6752
Marie Amougou-AtsamaService de Virologie, Centre Pasteur du Cameroun, Yaoundé, Cameroun.
Samira Zoa-AssoumouLaboratoire de Bactériologie-Virologie, Laboratoire de Référence IST-SIDA, Université des Sciences de la Santé, Owendo, Gabon.
Hervé M'boyis KamdemLaboratoire de Bactériologie-Virologie, Laboratoire de Référence IST-SIDA, Université des Sciences de la Santé, Owendo, Gabon.
Guy Francis Nzengui-NzenguiLaboratoire de Bactériologie-Virologie, Laboratoire de Référence IST-SIDA, Université des Sciences de la Santé, Owendo, Gabon.
Angélique Ndojyi-MbiguinoLaboratoire de Bactériologie-Virologie, Laboratoire de Référence IST-SIDA, Université des Sciences de la Santé, Owendo, Gabon.
Richard NjouomService de Virologie, Centre Pasteur du Cameroun, Yaoundé, Cameroun.
Sandrine François-SouquièreUnité Mixte de Recherches VIH et Maladies Infectieuses Associées (UMR VIH-MIA), Centre International de Recherches Médicales (CIRMF), Libreville, Gabon.
Université des Sciences de la Santé · GACentre Pasteur du Cameroun · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA). We used Monolisa HBsAg ULTRA, Anti-HBc Plus and Anti-HBs Plus EIA kits for serological analyses. HBV DNA viral load (HBV DNA VL) was determined by real time PCR and molecular characterization of HBV strains was performed by sequencing and phylogenetic analysis of partial HBV surface and core genes. At all, 70.2% of patients were under antiretroviral therapy. The prevalence of HBsAg was 8.8% (43/487). Detectable HBV DNA was found in 69.7% (30/43) of HBsAg positive patients and in 17.5% (24/137) HBsAg negative patients. HBV DNA VL was significantly higher among patient with CD4 cell counts less than 200 cells/mm3 than those with CD4 cell counts greater than 500 cells/mm3 (p = 0.008). We confirmed the presence of HBV sub-genotypes QS-A3 (40%), and A4 (20%) and HBV-E genotype (40%). The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif. Occult hepatitis B infection (OBI) was found in patients with isolated HBcAb and among patients who had completed their HBsAg seroconversion. We detected HBV DNA for one patient without any HBV serological marker. This study provides a new landmark for the comprehension of HBV infection in PLHA in urban areas. OBI enhances HBV DNA prevalence and should be investigated in all HBsAg negative individuals.

Indexed as

AdolescentAdultCD4 Lymphocyte CountDNA, ViralFemaleGabonHepatitis BHepatitis B Surface AntigensHepatitis B virusHIV InfectionsHumansMaleMiddle AgedViral LoadYoung AdultDNA, ViralHepatitis B Surface Antigens

Identifiers

PMID29315352
PMCPMC5760027
OpenAlexW2783984624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.